1

2

3
Alfred P Spada, Michael R Myers, Martin P Maguire, Paul E Persons: Bis mono-and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase. Aventis Pharmaceuticals Products, Synnestvedt & Lechner, May 2, 2000: US06057320 (61 worldwide citation)

This invention relates to bis mono- and/or bicyclic aryl and/or heteroaryl compounds exhibiting protein tyrosine kinase inhibition activity. More specifically, it relates to the method of inhibiting abnormal cell proliferation in a patient suffering from a disorder characterized by such proliferatio ...


4
Scott I Klein, Kevin R Guertin, Alfred P Spada: Substituted n-[(aminoiminomethyl or aminomethyl)phenyl]propyl amides. Aventis Pharmaceuticals Products, Ross J Oehler, June 27, 2000: US06080767 (53 worldwide citation)

The compounds according to the invention are substituted N-[(aminoiminomethyl or aminomethyl)phenyl]propyl amides of formula I herein which exhibit useful pharmacological activity and accordingly are incorporated into pharmaceutical compositions and used in the treatment of patients suffering from c ...


5

6
Andre Uzan, Alain H Curaudeau, Robert J Leadley, Christopher T Dunwiddie, Mark H Perrone: Pharmaceutical composition comprising a compound having anti-Xa activity and a platelet aggregation antagonist compound. Aventis Pharmaceuticals Products, Raymond S Parker III, Christine M Hansen, Ross J Oehler, August 15, 2000: US06103705 (20 worldwide citation)

The invention is also directed to pharmaceutical composition comprising a compound having anti-Xa activity, a platelet aggregation antagonist compound and a pharmaceutically acceptable carrier. The invention is also directed to a method of treating or preventing a thrombogenic condition associated w ...


7
Patrick Benoit, Eric Bruckert, Patrice Denefle, Nicolas Duverger, Jean Charles Fruchart, Gérald Luc, Gérard Turpin, Gerd Assmann, Harald Funke: Variants of apolipoprotein A-I. Aventis Pharmaceuticals Products, F Aaron Dubberley, Karen I Krupen, July 10, 2001: US06258596 (13 worldwide citation)

The present invention relates to variants of the human apolipoproteine A-I comprising a cystein in position 151, the corresponding nucleic acids and the vectors containing them. It also relates to pharmaceutical compositions comprising said elements and their utilization, particularly in genic thera ...


8
Jaye Michael, Lynch Kevin J, Amin Dilip V, Doan Kim Anh Thi, Marchadier Dawn, Maugeais Cyrille, Rader Daniel J, Krawiec John A, South Victoria J: Compositions and methods for effecting the levels of cholesterol. Aventis Pharmaceuticals Products, The Trustees Of The University Of Pennsylvania, Jaye Michael, Lynch Kevin J, Amin Dilip V, Doan Kim Anh Thi, Marchadier Dawn, Maugeais Cyrille, Rader Daniel J, Krawiec John A, South Victoria J, BARRON Alexis, October 5, 2000: WO/2000/057837 (9 worldwide citation)

Compositions and methods for raising the level of HDL cholesterol and apolipoprotein AI in a patient and for lowering the levels of VLDL cholesterol and LDL cholesterol in a patient, including compositions and methods which effect the expression of a gene, LIPG, which encodes a lipase enzyme that is ...


9
Larry K Truesdale, James P Sherbine, Benoit J Vanasse: Process for preparing 2,4- dihydroxypyridine and 2,4- dihydroxy-3-nitropyridine. Aventis Pharmaceuticals Products, Irving Newman, October 23, 2001: US06307054 (8 worldwide citation)

The present invention is directed to a process for preparing 2,4-dihydroxy-pyridine comprising heating a compound of the formula A


10
Zofia J Chrzan, James J Mencel, David Toledo Velasquez, Vincent Windisch, Rick G Woodward, Diane C Salazar deceased, Narasimha M Vemuri, Anthony J Gardetto, Matthew R Powers, Gregory G Kubiak, Robert C Liu, Benoit J Vanasse, James P Sherbine, Walter Rodriguez, Adam W Sledeski: Stable non-hygroscopic crystalline form of N-[N-[N-4-(piperidin-4-yl)butanoyl)-N-ethylglycyl] aspartyl]-L-.beta.-cyclohexyl alanine amide. Aventis Pharmaceuticals Products, Irving Newman, November 28, 2000: US06153588 (6 worldwide citation)

The invention is directed to a non-hygroscopic stable crystalline form of the antithrombotic compound N-[N-[N-(4-piperdin-4-yl)butanoyl)-N-ethylglycyl]-(L)-aspartyl]-(L)-.beta. -cyclohexyl-alanine amide, to processes for preparing said stable crystalline form, to a pharmaceutical composition thereof ...